...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Not adding up!

"The current stock price is not surprising to me because the market doesn't pay up today for events that are likely years down the road (the registration enabling studies)."

Ya maybe if you were talking about your beauty BTI pre-clinical/beginner stage company but your not.

Look at Zen's collaborations with multiple BP's & how many HUMAN trials they have been done & still doing.Look how much PP's were done for $$$ wise in the past & recently & it makes your comments look like pure bs IMO & with all your happy happy talk yout sure aren't buying many if any fella.

IMO anybody that feels our share value performance over the last 8 years is par for the course & is happy with a .27 SP & is not expecting anything for a few more years is talking pure bs or your shorting the stock or your Mc's bro or close friend or a small timer playing all puffy with 5k shares. Either way , anyway , not a good look.

Share
New Message
Please login to post a reply